Blood-brain barrier in drug discovery: optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Hoboken, New Jersey
Wiley
[2015]
|
| Schlagworte: | |
| Online-Zugang: | TUM01 Volltext |
| Beschreibung: | 1 Online-Ressource (xiv, 586 Seiten) Illustrationen |
| ISBN: | 9781118788547 1118788540 9781118788523 1118788524 9781118788493 1118788494 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV042795864 | ||
| 003 | DE-604 | ||
| 005 | 20160216 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 150902s2015 |||| o||u| ||||||eng d | ||
| 020 | |a 9781118788547 |c Online |9 978-1-118-78854-7 | ||
| 020 | |a 1118788540 |9 1-118-78854-0 | ||
| 020 | |a 9781118788523 |9 978-1-118-78852-3 | ||
| 020 | |a 1118788524 |9 1-118-78852-4 | ||
| 020 | |a 9781118788493 |9 978-1-118-78849-3 | ||
| 020 | |a 1118788494 |9 1-118-78849-4 | ||
| 035 | |a (ZDB-4-NLEBK)935074 | ||
| 035 | |a (OCoLC)893389733 | ||
| 035 | |a (DE-599)BVBBV042795864 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-91 | ||
| 082 | 0 | |a 615.7/8 |2 23 | |
| 084 | |a VS 7100 |0 (DE-625)147698:253 |2 rvk | ||
| 100 | 1 | |a Di, Li |4 edt | |
| 245 | 1 | 0 | |a Blood-brain barrier in drug discovery |b optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs |c edited by Li Di, Edward H. Kerns |
| 246 | 1 | 3 | |a Optimizing brain exposure of central nervous system drugs and minimizing brain side effects for peripheral drugs |
| 264 | 1 | |a Hoboken, New Jersey |b Wiley |c [2015] | |
| 300 | |a 1 Online-Ressource (xiv, 586 Seiten) |b Illustrationen | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 505 | 8 | |a Includes bibliographical references and index | |
| 505 | 8 | |a Machine generated contents note: Summary List of Chapters1. Overview/Introduction / Li Di (Pfizer Inc.), Edward H. Kerns (Pharmacokinetics of Brain Exposure)2. Pharmacokinetics of CNS penetration / Andreas Reichel (Bayer)3. Free Drug Hyposthesis for CNS Drug Candidates / Xingrong Liu (Genentech)4. Species Differences and impact of desease state on BBB / Jean-Marie Nicolas (UCB Pharma S.A.)Mechanisms of Drugs Across the Blood-Brain Barrier5. Passive diffusion permeability of the BBB -- examples and SAR / Phil Jeffrey (GSK)6. Efflux transport at the BBB -- examples and SAR / Jerome Hochman (Merck)7. Uptake transport at the BBB -- examples and SAR / Zack Cheng (AstraZeneca)8. Uptake of proteins and antibodies at the BBB / William Pardridge (UCLA)Predicting and Measuring Brain Exposure of Drugs9. In silico tools for assessing brain exposure / Hongming Chen (AstraZeneca)10. In vitro assays for assessing BBB permeability -- | |
| 505 | 8 | |a - vascular cells, artificial membranes, brain slice, cell uptake / Winfried Neuhaus (University of Vienna)11. Human-based in vitro endothelial cell models / Eric Shusta (University of Wisconsin)12. In vitro assays for assessing brain binding / Li Di (Pfizer)13. In vivo studies of brain exposure / Edward H. Kerns14. PBPK models for BBB / Elizabeth de Lange (Leiden University)15. PK/PD modeling of CNS drug candidates / Johan Gabrielsson (Swedish University)16. Microdialysis to assess free drug concentration in brain / William Kielbasa (Lilly)17. Imaging technique for CNS drug discovery / Lei Zhang (Pfizer Inc.)Modulating Brain Penetration of Leads During Drug Discovery18. Designing CNS drugs for optimal brain exposure / Zoran Rankovic (Lilly)19. Case studies of CNS drug optimization -- | |
| 505 | 8 | |a - medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts (Harvard NeuroDiscovery Center)20. Designing peripheral drugs for minimal brain exposue / Peter Bungay (Pfizer)21. Case studies of non-CNS drugs to minimize brain penetration -- Nonsudative antihistamines / Andrew Crowe (Curtin University)Case Studies in CNS Drug Discovery22. Case study 1 on discovery of a successful CNS drug -- Fycompa (AMPA Receptor Antagonist) / Andrew Satlin and Antonio Laurenza (Eisai)23. Case study 2 on discovery of a successful CNS drug -- Vortioxetine (Serotonin Modulator and Stimulator) / Benny Bang-Andersen (Lundbeck)Drug Delivery Techniques to CNS24. Brain delivery using nanotechnology / Xinguo Jiang (Fudan University)25. Intranasal delivery to CNS / Lisbeth Illum (University of Nottingham)Future Prospective in Blood Brain Barrier Advancement26. Conclusion Remarks / Joan Abbott (King's College) | |
| 505 | 8 | |a "Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher | |
| 650 | 4 | |a Blood-Brain Barrier / metabolism | |
| 650 | 4 | |a Central Nervous System Agents / pharmacokinetics | |
| 650 | 4 | |a Blood-Brain Barrier / drug effects | |
| 650 | 4 | |a Central Nervous System Diseases / drug therapy | |
| 650 | 4 | |a Drug Discovery / methods | |
| 650 | 4 | |a Drug-Related Side Effects and Adverse Reactions / prevention & control | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Blood-brain barrier |x Metabolism | |
| 650 | 4 | |a Drug development | |
| 650 | 0 | 7 | |a Wirkstofffreisetzung |0 (DE-588)4190018-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelforschung |0 (DE-588)4003120-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Blut-Hirn-Schranke |0 (DE-588)4007279-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Neuropharmakologie |0 (DE-588)4041896-0 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Blut-Hirn-Schranke |0 (DE-588)4007279-4 |D s |
| 689 | 0 | 1 | |a Neuropharmakologie |0 (DE-588)4041896-0 |D s |
| 689 | 0 | 2 | |a Arzneimittelforschung |0 (DE-588)4003120-2 |D s |
| 689 | 0 | 3 | |a Wirkstofffreisetzung |0 (DE-588)4190018-2 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a Kerns, Edward Harvel |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe, Hardcover |z 978-1-118-78835-6 |
| 856 | 4 | 0 | |u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=935074 |x Aggregator |3 Volltext |
| 912 | |a ZDB-4-NLEBK | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-028225637 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=935074 |l TUM01 |p ZDB-4-NLEBK |q TUM_PDA_EBSCOMED_gekauft |x Aggregator |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804175029025374208 |
|---|---|
| any_adam_object | |
| author2 | Di, Li Kerns, Edward Harvel |
| author2_role | edt edt |
| author2_variant | l d ld e h k eh ehk |
| author_facet | Di, Li Kerns, Edward Harvel |
| building | Verbundindex |
| bvnumber | BV042795864 |
| classification_rvk | VS 7100 |
| collection | ZDB-4-NLEBK |
| contents | Includes bibliographical references and index Machine generated contents note: Summary List of Chapters1. Overview/Introduction / Li Di (Pfizer Inc.), Edward H. Kerns (Pharmacokinetics of Brain Exposure)2. Pharmacokinetics of CNS penetration / Andreas Reichel (Bayer)3. Free Drug Hyposthesis for CNS Drug Candidates / Xingrong Liu (Genentech)4. Species Differences and impact of desease state on BBB / Jean-Marie Nicolas (UCB Pharma S.A.)Mechanisms of Drugs Across the Blood-Brain Barrier5. Passive diffusion permeability of the BBB -- examples and SAR / Phil Jeffrey (GSK)6. Efflux transport at the BBB -- examples and SAR / Jerome Hochman (Merck)7. Uptake transport at the BBB -- examples and SAR / Zack Cheng (AstraZeneca)8. Uptake of proteins and antibodies at the BBB / William Pardridge (UCLA)Predicting and Measuring Brain Exposure of Drugs9. In silico tools for assessing brain exposure / Hongming Chen (AstraZeneca)10. In vitro assays for assessing BBB permeability -- - vascular cells, artificial membranes, brain slice, cell uptake / Winfried Neuhaus (University of Vienna)11. Human-based in vitro endothelial cell models / Eric Shusta (University of Wisconsin)12. In vitro assays for assessing brain binding / Li Di (Pfizer)13. In vivo studies of brain exposure / Edward H. Kerns14. PBPK models for BBB / Elizabeth de Lange (Leiden University)15. PK/PD modeling of CNS drug candidates / Johan Gabrielsson (Swedish University)16. Microdialysis to assess free drug concentration in brain / William Kielbasa (Lilly)17. Imaging technique for CNS drug discovery / Lei Zhang (Pfizer Inc.)Modulating Brain Penetration of Leads During Drug Discovery18. Designing CNS drugs for optimal brain exposure / Zoran Rankovic (Lilly)19. Case studies of CNS drug optimization -- - medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts (Harvard NeuroDiscovery Center)20. Designing peripheral drugs for minimal brain exposue / Peter Bungay (Pfizer)21. Case studies of non-CNS drugs to minimize brain penetration -- Nonsudative antihistamines / Andrew Crowe (Curtin University)Case Studies in CNS Drug Discovery22. Case study 1 on discovery of a successful CNS drug -- Fycompa (AMPA Receptor Antagonist) / Andrew Satlin and Antonio Laurenza (Eisai)23. Case study 2 on discovery of a successful CNS drug -- Vortioxetine (Serotonin Modulator and Stimulator) / Benny Bang-Andersen (Lundbeck)Drug Delivery Techniques to CNS24. Brain delivery using nanotechnology / Xinguo Jiang (Fudan University)25. Intranasal delivery to CNS / Lisbeth Illum (University of Nottingham)Future Prospective in Blood Brain Barrier Advancement26. Conclusion Remarks / Joan Abbott (King's College) "Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher |
| ctrlnum | (ZDB-4-NLEBK)935074 (OCoLC)893389733 (DE-599)BVBBV042795864 |
| dewey-full | 615.7/8 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.7/8 |
| dewey-search | 615.7/8 |
| dewey-sort | 3615.7 18 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>06669nmm a2200721zc 4500</leader><controlfield tag="001">BV042795864</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20160216 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">150902s2015 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118788547</subfield><subfield code="c">Online</subfield><subfield code="9">978-1-118-78854-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118788540</subfield><subfield code="9">1-118-78854-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118788523</subfield><subfield code="9">978-1-118-78852-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118788524</subfield><subfield code="9">1-118-78852-4</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781118788493</subfield><subfield code="9">978-1-118-78849-3</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1118788494</subfield><subfield code="9">1-118-78849-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-NLEBK)935074</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)893389733</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV042795864</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-91</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.7/8</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 7100</subfield><subfield code="0">(DE-625)147698:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Di, Li</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Blood-brain barrier in drug discovery</subfield><subfield code="b">optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs</subfield><subfield code="c">edited by Li Di, Edward H. Kerns</subfield></datafield><datafield tag="246" ind1="1" ind2="3"><subfield code="a">Optimizing brain exposure of central nervous system drugs and minimizing brain side effects for peripheral drugs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Hoboken, New Jersey</subfield><subfield code="b">Wiley</subfield><subfield code="c">[2015]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (xiv, 586 Seiten)</subfield><subfield code="b">Illustrationen</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Includes bibliographical references and index</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Machine generated contents note: Summary List of Chapters1. Overview/Introduction / Li Di (Pfizer Inc.), Edward H. Kerns (Pharmacokinetics of Brain Exposure)2. Pharmacokinetics of CNS penetration / Andreas Reichel (Bayer)3. Free Drug Hyposthesis for CNS Drug Candidates / Xingrong Liu (Genentech)4. Species Differences and impact of desease state on BBB / Jean-Marie Nicolas (UCB Pharma S.A.)Mechanisms of Drugs Across the Blood-Brain Barrier5. Passive diffusion permeability of the BBB -- examples and SAR / Phil Jeffrey (GSK)6. Efflux transport at the BBB -- examples and SAR / Jerome Hochman (Merck)7. Uptake transport at the BBB -- examples and SAR / Zack Cheng (AstraZeneca)8. Uptake of proteins and antibodies at the BBB / William Pardridge (UCLA)Predicting and Measuring Brain Exposure of Drugs9. In silico tools for assessing brain exposure / Hongming Chen (AstraZeneca)10. In vitro assays for assessing BBB permeability -- </subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a"> - vascular cells, artificial membranes, brain slice, cell uptake / Winfried Neuhaus (University of Vienna)11. Human-based in vitro endothelial cell models / Eric Shusta (University of Wisconsin)12. In vitro assays for assessing brain binding / Li Di (Pfizer)13. In vivo studies of brain exposure / Edward H. Kerns14. PBPK models for BBB / Elizabeth de Lange (Leiden University)15. PK/PD modeling of CNS drug candidates / Johan Gabrielsson (Swedish University)16. Microdialysis to assess free drug concentration in brain / William Kielbasa (Lilly)17. Imaging technique for CNS drug discovery / Lei Zhang (Pfizer Inc.)Modulating Brain Penetration of Leads During Drug Discovery18. Designing CNS drugs for optimal brain exposure / Zoran Rankovic (Lilly)19. Case studies of CNS drug optimization -- </subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a"> - medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts (Harvard NeuroDiscovery Center)20. Designing peripheral drugs for minimal brain exposue / Peter Bungay (Pfizer)21. Case studies of non-CNS drugs to minimize brain penetration -- Nonsudative antihistamines / Andrew Crowe (Curtin University)Case Studies in CNS Drug Discovery22. Case study 1 on discovery of a successful CNS drug -- Fycompa (AMPA Receptor Antagonist) / Andrew Satlin and Antonio Laurenza (Eisai)23. Case study 2 on discovery of a successful CNS drug -- Vortioxetine (Serotonin Modulator and Stimulator) / Benny Bang-Andersen (Lundbeck)Drug Delivery Techniques to CNS24. Brain delivery using nanotechnology / Xinguo Jiang (Fudan University)25. Intranasal delivery to CNS / Lisbeth Illum (University of Nottingham)Future Prospective in Blood Brain Barrier Advancement26. Conclusion Remarks / Joan Abbott (King's College)</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">"Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Blood-Brain Barrier / metabolism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central Nervous System Agents / pharmacokinetics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Blood-Brain Barrier / drug effects</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central Nervous System Diseases / drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Discovery / methods</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug-Related Side Effects and Adverse Reactions / prevention & control</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Blood-brain barrier</subfield><subfield code="x">Metabolism</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug development</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Wirkstofffreisetzung</subfield><subfield code="0">(DE-588)4190018-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelforschung</subfield><subfield code="0">(DE-588)4003120-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Blut-Hirn-Schranke</subfield><subfield code="0">(DE-588)4007279-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Neuropharmakologie</subfield><subfield code="0">(DE-588)4041896-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Blut-Hirn-Schranke</subfield><subfield code="0">(DE-588)4007279-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Neuropharmakologie</subfield><subfield code="0">(DE-588)4041896-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelforschung</subfield><subfield code="0">(DE-588)4003120-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Wirkstofffreisetzung</subfield><subfield code="0">(DE-588)4190018-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kerns, Edward Harvel</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe, Hardcover</subfield><subfield code="z">978-1-118-78835-6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=935074</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-NLEBK</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-028225637</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=935074</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-4-NLEBK</subfield><subfield code="q">TUM_PDA_EBSCOMED_gekauft</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV042795864 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:09:47Z |
| institution | BVB |
| isbn | 9781118788547 1118788540 9781118788523 1118788524 9781118788493 1118788494 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-028225637 |
| oclc_num | 893389733 |
| open_access_boolean | |
| owner | DE-91 DE-BY-TUM |
| owner_facet | DE-91 DE-BY-TUM |
| physical | 1 Online-Ressource (xiv, 586 Seiten) Illustrationen |
| psigel | ZDB-4-NLEBK ZDB-4-NLEBK TUM_PDA_EBSCOMED_gekauft |
| publishDate | 2015 |
| publishDateSearch | 2015 |
| publishDateSort | 2015 |
| publisher | Wiley |
| record_format | marc |
| spelling | Di, Li edt Blood-brain barrier in drug discovery optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs edited by Li Di, Edward H. Kerns Optimizing brain exposure of central nervous system drugs and minimizing brain side effects for peripheral drugs Hoboken, New Jersey Wiley [2015] 1 Online-Ressource (xiv, 586 Seiten) Illustrationen txt rdacontent c rdamedia cr rdacarrier Includes bibliographical references and index Machine generated contents note: Summary List of Chapters1. Overview/Introduction / Li Di (Pfizer Inc.), Edward H. Kerns (Pharmacokinetics of Brain Exposure)2. Pharmacokinetics of CNS penetration / Andreas Reichel (Bayer)3. Free Drug Hyposthesis for CNS Drug Candidates / Xingrong Liu (Genentech)4. Species Differences and impact of desease state on BBB / Jean-Marie Nicolas (UCB Pharma S.A.)Mechanisms of Drugs Across the Blood-Brain Barrier5. Passive diffusion permeability of the BBB -- examples and SAR / Phil Jeffrey (GSK)6. Efflux transport at the BBB -- examples and SAR / Jerome Hochman (Merck)7. Uptake transport at the BBB -- examples and SAR / Zack Cheng (AstraZeneca)8. Uptake of proteins and antibodies at the BBB / William Pardridge (UCLA)Predicting and Measuring Brain Exposure of Drugs9. In silico tools for assessing brain exposure / Hongming Chen (AstraZeneca)10. In vitro assays for assessing BBB permeability -- - vascular cells, artificial membranes, brain slice, cell uptake / Winfried Neuhaus (University of Vienna)11. Human-based in vitro endothelial cell models / Eric Shusta (University of Wisconsin)12. In vitro assays for assessing brain binding / Li Di (Pfizer)13. In vivo studies of brain exposure / Edward H. Kerns14. PBPK models for BBB / Elizabeth de Lange (Leiden University)15. PK/PD modeling of CNS drug candidates / Johan Gabrielsson (Swedish University)16. Microdialysis to assess free drug concentration in brain / William Kielbasa (Lilly)17. Imaging technique for CNS drug discovery / Lei Zhang (Pfizer Inc.)Modulating Brain Penetration of Leads During Drug Discovery18. Designing CNS drugs for optimal brain exposure / Zoran Rankovic (Lilly)19. Case studies of CNS drug optimization -- - medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts (Harvard NeuroDiscovery Center)20. Designing peripheral drugs for minimal brain exposue / Peter Bungay (Pfizer)21. Case studies of non-CNS drugs to minimize brain penetration -- Nonsudative antihistamines / Andrew Crowe (Curtin University)Case Studies in CNS Drug Discovery22. Case study 1 on discovery of a successful CNS drug -- Fycompa (AMPA Receptor Antagonist) / Andrew Satlin and Antonio Laurenza (Eisai)23. Case study 2 on discovery of a successful CNS drug -- Vortioxetine (Serotonin Modulator and Stimulator) / Benny Bang-Andersen (Lundbeck)Drug Delivery Techniques to CNS24. Brain delivery using nanotechnology / Xinguo Jiang (Fudan University)25. Intranasal delivery to CNS / Lisbeth Illum (University of Nottingham)Future Prospective in Blood Brain Barrier Advancement26. Conclusion Remarks / Joan Abbott (King's College) "Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher Blood-Brain Barrier / metabolism Central Nervous System Agents / pharmacokinetics Blood-Brain Barrier / drug effects Central Nervous System Diseases / drug therapy Drug Discovery / methods Drug-Related Side Effects and Adverse Reactions / prevention & control MEDICAL / Pharmacology bisacsh Medizin Blood-brain barrier Metabolism Drug development Wirkstofffreisetzung (DE-588)4190018-2 gnd rswk-swf Arzneimittelforschung (DE-588)4003120-2 gnd rswk-swf Blut-Hirn-Schranke (DE-588)4007279-4 gnd rswk-swf Neuropharmakologie (DE-588)4041896-0 gnd rswk-swf Blut-Hirn-Schranke (DE-588)4007279-4 s Neuropharmakologie (DE-588)4041896-0 s Arzneimittelforschung (DE-588)4003120-2 s Wirkstofffreisetzung (DE-588)4190018-2 s 1\p DE-604 Kerns, Edward Harvel edt Erscheint auch als Druck-Ausgabe, Hardcover 978-1-118-78835-6 http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=935074 Aggregator Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Blood-brain barrier in drug discovery optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs Includes bibliographical references and index Machine generated contents note: Summary List of Chapters1. Overview/Introduction / Li Di (Pfizer Inc.), Edward H. Kerns (Pharmacokinetics of Brain Exposure)2. Pharmacokinetics of CNS penetration / Andreas Reichel (Bayer)3. Free Drug Hyposthesis for CNS Drug Candidates / Xingrong Liu (Genentech)4. Species Differences and impact of desease state on BBB / Jean-Marie Nicolas (UCB Pharma S.A.)Mechanisms of Drugs Across the Blood-Brain Barrier5. Passive diffusion permeability of the BBB -- examples and SAR / Phil Jeffrey (GSK)6. Efflux transport at the BBB -- examples and SAR / Jerome Hochman (Merck)7. Uptake transport at the BBB -- examples and SAR / Zack Cheng (AstraZeneca)8. Uptake of proteins and antibodies at the BBB / William Pardridge (UCLA)Predicting and Measuring Brain Exposure of Drugs9. In silico tools for assessing brain exposure / Hongming Chen (AstraZeneca)10. In vitro assays for assessing BBB permeability -- - vascular cells, artificial membranes, brain slice, cell uptake / Winfried Neuhaus (University of Vienna)11. Human-based in vitro endothelial cell models / Eric Shusta (University of Wisconsin)12. In vitro assays for assessing brain binding / Li Di (Pfizer)13. In vivo studies of brain exposure / Edward H. Kerns14. PBPK models for BBB / Elizabeth de Lange (Leiden University)15. PK/PD modeling of CNS drug candidates / Johan Gabrielsson (Swedish University)16. Microdialysis to assess free drug concentration in brain / William Kielbasa (Lilly)17. Imaging technique for CNS drug discovery / Lei Zhang (Pfizer Inc.)Modulating Brain Penetration of Leads During Drug Discovery18. Designing CNS drugs for optimal brain exposure / Zoran Rankovic (Lilly)19. Case studies of CNS drug optimization -- - medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts (Harvard NeuroDiscovery Center)20. Designing peripheral drugs for minimal brain exposue / Peter Bungay (Pfizer)21. Case studies of non-CNS drugs to minimize brain penetration -- Nonsudative antihistamines / Andrew Crowe (Curtin University)Case Studies in CNS Drug Discovery22. Case study 1 on discovery of a successful CNS drug -- Fycompa (AMPA Receptor Antagonist) / Andrew Satlin and Antonio Laurenza (Eisai)23. Case study 2 on discovery of a successful CNS drug -- Vortioxetine (Serotonin Modulator and Stimulator) / Benny Bang-Andersen (Lundbeck)Drug Delivery Techniques to CNS24. Brain delivery using nanotechnology / Xinguo Jiang (Fudan University)25. Intranasal delivery to CNS / Lisbeth Illum (University of Nottingham)Future Prospective in Blood Brain Barrier Advancement26. Conclusion Remarks / Joan Abbott (King's College) "Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher Blood-Brain Barrier / metabolism Central Nervous System Agents / pharmacokinetics Blood-Brain Barrier / drug effects Central Nervous System Diseases / drug therapy Drug Discovery / methods Drug-Related Side Effects and Adverse Reactions / prevention & control MEDICAL / Pharmacology bisacsh Medizin Blood-brain barrier Metabolism Drug development Wirkstofffreisetzung (DE-588)4190018-2 gnd Arzneimittelforschung (DE-588)4003120-2 gnd Blut-Hirn-Schranke (DE-588)4007279-4 gnd Neuropharmakologie (DE-588)4041896-0 gnd |
| subject_GND | (DE-588)4190018-2 (DE-588)4003120-2 (DE-588)4007279-4 (DE-588)4041896-0 |
| title | Blood-brain barrier in drug discovery optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs |
| title_alt | Optimizing brain exposure of central nervous system drugs and minimizing brain side effects for peripheral drugs |
| title_auth | Blood-brain barrier in drug discovery optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs |
| title_exact_search | Blood-brain barrier in drug discovery optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs |
| title_full | Blood-brain barrier in drug discovery optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs edited by Li Di, Edward H. Kerns |
| title_fullStr | Blood-brain barrier in drug discovery optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs edited by Li Di, Edward H. Kerns |
| title_full_unstemmed | Blood-brain barrier in drug discovery optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs edited by Li Di, Edward H. Kerns |
| title_short | Blood-brain barrier in drug discovery |
| title_sort | blood brain barrier in drug discovery optimizing brain exposure of cns drugs and minimizing brain side effects for peripheral drugs |
| title_sub | optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs |
| topic | Blood-Brain Barrier / metabolism Central Nervous System Agents / pharmacokinetics Blood-Brain Barrier / drug effects Central Nervous System Diseases / drug therapy Drug Discovery / methods Drug-Related Side Effects and Adverse Reactions / prevention & control MEDICAL / Pharmacology bisacsh Medizin Blood-brain barrier Metabolism Drug development Wirkstofffreisetzung (DE-588)4190018-2 gnd Arzneimittelforschung (DE-588)4003120-2 gnd Blut-Hirn-Schranke (DE-588)4007279-4 gnd Neuropharmakologie (DE-588)4041896-0 gnd |
| topic_facet | Blood-Brain Barrier / metabolism Central Nervous System Agents / pharmacokinetics Blood-Brain Barrier / drug effects Central Nervous System Diseases / drug therapy Drug Discovery / methods Drug-Related Side Effects and Adverse Reactions / prevention & control MEDICAL / Pharmacology Medizin Blood-brain barrier Metabolism Drug development Wirkstofffreisetzung Arzneimittelforschung Blut-Hirn-Schranke Neuropharmakologie |
| url | http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=935074 |
| work_keys_str_mv | AT dili bloodbrainbarrierindrugdiscoveryoptimizingbrainexposureofcnsdrugsandminimizingbrainsideeffectsforperipheraldrugs AT kernsedwardharvel bloodbrainbarrierindrugdiscoveryoptimizingbrainexposureofcnsdrugsandminimizingbrainsideeffectsforperipheraldrugs AT dili optimizingbrainexposureofcentralnervoussystemdrugsandminimizingbrainsideeffectsforperipheraldrugs AT kernsedwardharvel optimizingbrainexposureofcentralnervoussystemdrugsandminimizingbrainsideeffectsforperipheraldrugs |